Stress and the gut: Pathophysiology, clinical consequences, diagnostic approach and treatment options

Journal of Physiology and Pharmacology

Volumn 62, Issue 6, 2011, Pages 591-599

  Konturek, P C ^a   Brzozowski, T ^b   Konturek, S J ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Brain gut axis; Gastrointestinal tract; Intestinal bacterial overgrowth; Irritable bowel syndrome; Microbiota; Probiotics; Stress

Indexed keywords

ALOSETRON; AMITRIPTYLINE; CHLORIDE CHANNEL OPENER; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYTOKINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; GASTROINTESTINAL AGENT; ISPAGULA; LOPERAMIDE; LUBIPROSTONE; MACROGOL; MELATONIN; MU OPIATE RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; PRUCALOPRIDE; RIFAXIMIN; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ABDOMINAL SONOGRAPHY; BEHAVIOR THERAPY; BLOOD EXAMINATION; BRAIN; BRAIN GUT AXIS; BREATH ANALYSIS; CARBOHYDRATE INTOLERANCE; CELIAC DISEASE SEROLOGY; COLON BIOPSY; COLONOSCOPY; CONSTIPATION; CYTOKINE RELEASE; DIAGNOSTIC PROCEDURE; DIARRHEA; DIET THERAPY; DOCTOR PATIENT RELATION; DRUG DOSE TITRATION; ECHOGRAPHY; ENTERITIS; ERADICATION THERAPY; EVENING DOSAGE; FECES ANALYSIS; FOOD ANTIGEN RELATED ADVERSE RESPONSE; FUNCTIONAL DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SECRETION; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; INTESTINAL DYSMOTILITY; INTESTINE BLOOD FLOW; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT EDUCATION; PEPTIC ULCER; REVIEW; SMALL INTESTINAL BACTERIAL OVERGROWTH; STRESS; TISSUE REGENERATION;

ANIMALS; ANTIDIARRHEALS; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84856866840     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Selye H. Syndrome produced by diverse nocuous agents. Nature 1936; 138: 32.
2. Bhatia V, Tandon RK. Stress and the gastrointestinal tract. J Gastroenterol Hepatol 2005; 20: 332-339.
3. Soderholm JD, Perdue MH. Stress and gastrointestinal tract. Stress and intestinal barrier function. Am J Physiol Gastrointest Liver Physiol 2001; 280: G7-G13.
4. Nakade Y, Fukuda H, Iwa M, et al. Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats. Am J Physiol Gastrointestinal Liver Physiol 2007; 292: G1037-G1044.
5. Konturek SJ, Brzozowski T, Konturek PC, Zwirska-Korczala K, Reiter RJ. Day/night differences in stress-induced gastric lesions in rats with an intact pineal gland or after pinealectomy. J Pineal Res 2008; 44: 408-415.
6. Lyte M, Vulchanova L, Brown DR. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell Tissue Res 2011; 343: 23-32.
7. Beaumont W. Experiments and Observations on the Gastric Juice and the Physiology of Digestion. Edinburgh, Maclachlan and Stewart, 1838.
8. Laranjeira C, Pachnis V. Enteric nervous system development: recent progress and future challenges. Auton Neurosci 2009; 151: 61-69.
9. Konturek SJ, Konturek JW. Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 2004; 55: 137-154.
10. Mayer EA. Tilisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62: 381-396.
11. Bonaz B, Sabate JM, Brain-gut axis dysfunction. Gastroenterol Clin Biol 2009; 33(Suppl. 1): S48-S58.
12. Taché Y, Bonaz B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J Clin Invest 2007; 117: 33-40.
13. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306-314.
14. Lyte M, Vulchanova L, Brown DR. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell Tissue Res 2011; 343: 23-32.
15. Konturek PC, Sliwowski Z, Koziel J, et al. Probiotic bacteria Escherichia coli strain Nissle 1917 attenuates acute gastric lesions induced by stress. J Physiol Pharmacol 2009; 60(Suppl 6): 41-48.
16. Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol 2007; 13: 3027-3030.
17. Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008; 57: 50-58.
18. Elsenbruch S, Rosenberger C, Enck P, Forsting M, Schedlowski M, Gizewski ER. Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 2010; 59: 489-495.
19. O'Malley D, Quigley EM, Dinan TG, Cryan JF. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? Brain Behav Immun 2011; 25: 1333-1341.
20. Stasi C, Orlandelli E. Role of the brain-gut axis in the pathophysiology of Crohn's disease. Dig Dis 2008; 26: 156-166.
21. Yang PC, Jury J, Söderholm JD, Sherman PM, McKay DM, Perdue MH. Chronic psychological stress in rats induces intestinal sensitization to luminal antigens. Am J Pathol 2006; 168: 104-114.
22. Mittal RK, Stewart WR, Ramahi M, Chen J, Tisdelle D. The effects of psychological stress on the esophagogastric junction pressure and swallow-induced relaxation. Gastroenterology 1994; 106: 1477-1484.
23. Mizyed I, Fass SS, Fass R. Review article: gastro-oesophageal reflux disease and psychological comorbidity. Aliment Pharmacol Ther 2009; 29: 351-358.
24. Li J, Brackbill RM, Stellman SD, et al. Gastroesophageal reflux symptoms and comorbid asthma and posttraumatic stress disorder following the 9/11 terrorist attacks on World Trade Center in New York City. Am J Gastroenterol 2011; 106: 1933-1941.
25. Perlman SE, Friedman S, Galea S, et al. Short-term and medium-term health effects of 9/11. Lancet 2011; 378: 925-934.
26. Yeomans ND. The ulcer sleuths: the search for the cause of peptic ulcers. J Gastroenterol Hepatol 2011; 26(Suppl 1): 35-41.
27. Konturek PC. Physiological, immunohistochemical and molecular aspects of gastric adaptation to stress, aspirin and to H. pylori-derived gastrotoxins. J Physiol Pharmacol 1997; 48: 3-42.
28. Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am 2009; 38: 245-265.
29. Konturek PC, Brzozowski T, Burnat G, et al. Role of brain-gut axis in healing of gastric ulcers. J Physiol Pharmacol 2004; 55: 179-192.
30. Brzozowski T, Konturek PC, Pajdo R, et al. Importance of brain-gut axis in the gastroprotection induced by gastric and remote preconditioning. J Physiol Pharmacol 2004; 55: 165-177.
31. Loyd RA. McClellan DA. Update on the evaluation and management of functional dyspepsia. Am Fam Physician 2011; 83: 547-552.
32. Kachintorn U. Epidemiology, approach and management of functional dyspepsia in Thailand. J Gastroenterol Hepatol 2011; 3: 32-34
33. Tack J, Talley NJ. Gastroduodenal disorders. Am J Gastroenterol 2011; 105: 757-763.
34. Camillieri M, Tack JF. Current medical treatments of dyspepsia and irritable bowel syndrome. Gastroenterol Clin North Am 2010; 39: 481-493.
35. Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 2009; 104: 1298-1313.
36. Li J, Norgard B, Precht DH, Olsen J. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark. Am J Gastroenterol 2004; 99: 1129-1133.
37. Israeli E, Hershcovici T, Berenshtein E, et al. The effect of restraint stress on the normal colon and on intestinal inflammation in a model of experimental colitis. Dig Dis Sci 2008; 53: 88-94.
38. Camara RJ, Ziegler R, Begre S, Schoepfer AM, von Kanel R. Swiss inflammatory bowel disease cohort study (SIBDCS) group. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. Digestion 2009; 80: 129-139.
39. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun 2011; 25: 397-407.
40. Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol 2010; 7: 565-581.
41. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011; 12: 453-466.
42. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Ann Rev Med 2011; 62: 381-396.
43. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491.
44. Clarke G, Quigley EM, Cryan JF, Dinan TG. Irritable bowel syndrome: towards biomarker identification. Trends Mol Med 2009; 15: 478-489.
45. Hammerle CW, Crowe SE. When to reconsider the diagnosis of irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 291-307.
46. Rubin G, De Wit N, Meineche-Schmidt V, Seifert B, Hall N, Hungin P. The diagnosis of IBS in primary care: consensus development using nominal group technique. Fam Pract 2006; 23: 687-692.
47. Zimmerman J. Extraintestinal symptoms in irritable bowel syndrome and inflammatory bowel diseases: nature, severity, and relationship to gastrointestinal symptoms. Dig Dis Sci 2003; 48: 743-749.
48. Keller J, Wedel T, Seidl H, et al. S3 guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM) to the definition, pathophysiology, diagnosis and treatment of intestinal motility. Z Gastroenterol 2011; 49: 374-390.
49. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for healthcare practitioners. J Gastroenterol Hepatol 2010; 25: 691-699.
50. Chang J Y, Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends Pharmacol Sci 2010; 31: 326-334.
51. Konturek PC, Brzozowski T, Konturek SJ. Gut clock: implication of circadian rhythms in the gastrointestinal tract. J Physiol Pharmacol 2011; 62: 139-150.
52. Bleser S. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. Curr Med Res Opin 2011; 27: 503-512.
53. Lewis JH. Alosetron for severe diarrhoea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol 2010; 4: 13-29.
54. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
55. Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011; 5: 253-266.
56. Awad RA, Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis 2010; 12: 1131-1138.
57. Manabe N, Rao AS, Wong BS, Camilleri M. Emerging pharmacologic therapies for irritable bowel syndrome. Curr Gastroenterol Rep 2010; 12: 408-416.
58. Camilleri M. New receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther 2010; 31: 35-46.
59. Pohl D, Tutuian R, Fried M. Pharmacologic treatment of constipation: what is new? Curr Opin Pharmacol 2008; 8: 724-728.
60. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009; 15: 1548-1553.
61. Gale JD, Houghton LA. Alpha 2 delta (α(2)δ) ligands, gabapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome. Front Pharmacol 2011; 2: 28.
62. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011; 14: 581-587.
63. Sainsbury A, Ford AC. Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therap Adv Gastroenterol 2011; 4: 115-127.
64. Yoon SL, Grundmann O, Koepp L, Farrell L. Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. Altern Med Rev 2011; 16: 134-151.
65. Magge S, Lembo A. Complementary and alternative medicine for the irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 245-253.